Ronald A. Peck, M.D. Chief Medical Officer and SVP, Clinical Development
first name I look into and wow, no surprise..... affiliated to BMS lol So they bring in a Yervoy doc, mixed in with Lemke the PS Targeting expert and combine a little Bavi into the picture and woolahhhh..
I still laugh at how Lemke tried to say they discovered flipped PS on the surface lol
Rolf, you better make it very clear that the late Dr. Philip Thorpe is the mastermind behind all of this and I hope Greg Lemke passes along some respect entering UTSWM
-----------------------------
Kolltan Pharmaceuticals Appoints Ronald A. Peck, M.D., Chief Medical Officer and SVP, Clinical Development
Aug 5, 2015
NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc. (“Kolltan” or the “Company”), a privately held clinical-stage company focused on the discovery and development of novel, best-in-class antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases, today announced the appointment of Ronald A. Peck, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development. Dr. Peck will lead the clinical development of Kolltan’s product pipeline and will report to President and Chief Executive Officer Gerald McMahon, Ph.D. Kolltan’s most advanced product candidates include KTN3379, which is in Phase 1b clinical trials, and KTN0158, which is anticipated to enter clinical trials in early 2016. Dr. Peck will succeed Carolyn F. Sidor, M.D., who will continue as a medical and regulatory consultant to the Company.
“Dr. Peck’s exceptional track record and experience in oncology clinical development and his accomplishments in immuno-oncology will contribute to the evaluation of our antibody therapeutics in oncology and other immune-related disorders.”
“We are pleased to welcome Ron to the Kolltan team as we are advancing KTN3379 in multiple clinical trials and progressing KTN0158 into clinical development,” stated Dr. McMahon. “Dr. Peck’s exceptional track record and experience in oncology clinical development and his accomplishments in immuno-oncology will contribute to the evaluation of our antibody therapeutics in oncology and other immune-related disorders.” Dr. McMahon added, “We greatly appreciate Carolyn’s hard work, mentorship, and clinical leadership over the past two years as she led the execution of our clinical development strategies. Furthermore, we appreciate her continued role to augment the team’s capabilities.”
Dr. Peck has over 15 years of extensive drug development expertise in oncology and other areas. Prior to joining Kolltan, Dr. Peck held roles of increasing responsibility at Bristol-Myers Squibb Company (“BMS”) since 2000, where he contributed to the successful development of multiple therapeutic drug products. Notably, Dr. Peck led the clinical development program for IXEMPRA® (ixabepilone), and he served most recently as Vice President, Global Development Lead for YERVOY® (ipilimumab), playing a key role in the approval and commercialization of this drug in all indications. Prior to his successful term at BMS, Dr. Peck was on the faculty at the University of Virginia in the division of hematology/oncology. Dr. Peck received his medical degree from Thomas Jefferson University and completed his residency in internal medicine and a fellowship in hematology and oncology at the Vincent Lombardi Cancer Center at Georgetown University, where he also went on to pursue a fellowship in Developmental Therapeutics. He is board-certified in medical oncology.
“I am very excited to join the Kolltan senior management team at this important time in the development of the Company. I look forward to working with the team in advancing the Company’s portfolio of innovative product candidates and bringing important new medicines to patients,” stated Dr. Peck. .. ..
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
AI
